Clinical Perspectives

Reshaping the Frontline Treatment Landscape of ES-SCLC

June 03, 2021


Although a number of second-line treatment options exist in the setting of extensive-stage small cell lung cancer (ES-SCLC), Bruna Pellini, MD, an assistant member at the Department of Thoracic Oncology at the H. Lee Moffitt Cancer Center and an assistant professor at Morsani College of Medicine at the University of South Florida, says that the decision for an individual patient to receive a novel agent or chemotherapy depends on one factor: their platinum-free interval.  

Dr. Bruna Pellini
Dr. Bruna Pellini

Pellini, in an interview with OncLive®, also compares the findings of the CASPIAN and IMpower133 trials and research efforts currently ongoing in ES-SCLC. Read the story here

Lung cancer screening could save your patient’s life. If you’d like to refer a patient to the Lung Cancer Screening Program at Moffitt Cancer Center, complete our online form or contacting a physician liaison for assistance.  As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.